These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 16176298)

  • 1. Plasma and Urine Levels of Glycosaminoglycans in Patients with Systemic Sclerosis and Their Relationship to Selected Interleukins and Marker of Early Kidney Injury.
    Kuźnik-Trocha K; Winsz-Szczotka K; Komosińska-Vassev K; Jura-Półtorak A; Miara A; Kotyla P; Olczyk K
    J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiology of gadolinium-associated systemic fibrosis.
    Wagner B; Drel V; Gorin Y
    Am J Physiol Renal Physiol; 2016 Jul; 311(1):F1-F11. PubMed ID: 27147669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis.
    Wermuth PJ; Jimenez SA
    J Immunol; 2012 Jul; 189(1):318-27. PubMed ID: 22649203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis.
    Riser BL; Bhagavathula N; Perone P; Garchow K; Xu Y; Fisher GJ; Najmabadi F; Attili D; Varani J
    J Cell Commun Signal; 2012 Jun; 6(2):97-105. PubMed ID: 22648571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of fibroblast proliferation by insoluble gadolinium salts.
    Bleavins K; Perone P; Naik M; Rehman M; Aslam MN; Dame MK; Meshinchi S; Bhagavathula N; Varani J
    Biol Trace Elem Res; 2012 Feb; 145(2):257-67. PubMed ID: 21882070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyaluronan as an immune regulator in human diseases.
    Jiang D; Liang J; Noble PW
    Physiol Rev; 2011 Jan; 91(1):221-64. PubMed ID: 21248167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects.
    DaSilva M; O'Brien Deming M; Fligiel SE; Dame MK; Johnson KJ; Swartz RD; Varani J
    Invest Radiol; 2010 Nov; 45(11):733-9. PubMed ID: 20661146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Collagenolytic activity is suppressed in organ-cultured human skin exposed to a gadolinium-based MRI contrast agent.
    Perone PA; Weber SL; DaSilva M; Paruchuri T; Bhagavathula N; Aslam MN; Dame MK; Johnson KJ; Swartz RD; Varani J
    Invest Radiol; 2010 Jan; 45(1):42-8. PubMed ID: 19996758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrogenic systemic fibrosis in liver disease: a systematic review.
    Mazhar SM; Shiehmorteza M; Kohl CA; Middleton MS; Sirlin CB
    J Magn Reson Imaging; 2009 Dec; 30(6):1313-22. PubMed ID: 19937937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent.
    Bhagavathula N; DaSilva M; Aslam MN; Dame MK; Warner RL; Xu Y; Fisher GJ; Johnson KJ; Swartz R; Varani J
    Invest Radiol; 2009 Aug; 44(8):433-9. PubMed ID: 19561517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gadolinium and nephrogenic systemic fibrosis: time to tighten practice.
    Mendichovszky IA; Marks SD; Simcock CM; Olsen OE
    Pediatr Radiol; 2008 May; 38(5):489-96; quiz 602-3. PubMed ID: 17943276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous mucinosis associated with dermatomyositis and nephrogenic fibrosing dermopathy: fibroblast hyaluronan synthesis and the effect of patient serum.
    Edward M; Fitzgerald L; Thind C; Leman J; Burden AD
    Br J Dermatol; 2007 Mar; 156(3):473-9. PubMed ID: 17300236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema.
    Kucher C; Xu X; Pasha T; Elenitsas R
    J Cutan Pathol; 2005 Aug; 32(7):484-90. PubMed ID: 16008692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis.
    Hamilton-Persaud K; Ezell LD; Macklin JG
    Nephrol Nurs J; 2007; 34(3):283-7; quiz 288. PubMed ID: 17644872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrogenic fibrosing dermopathy in a patient with acute renal failure never requiring dialysis.
    Cassis TB; Jackson JM; Sonnier GB; Callen JP
    Int J Dermatol; 2006 Jan; 45(1):56-9. PubMed ID: 16426379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scleromyxedema-like lesions of patients in renal failure contain hyaluronan: a possible pathophysiological mechanism.
    Neudecker BA; Stern R; Mark LA; Steinberg S
    J Cutan Pathol; 2005 Oct; 32(9):612-5. PubMed ID: 16176298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nephrogenic fibrosing dermopathy].
    Engelen JW; Kooistra MP; Canninga-van Dijk MR; Toonstra J; Sigurdsson V
    Ned Tijdschr Geneeskd; 2003 Dec; 147(49):2435-8. PubMed ID: 14694555
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.